137 related articles for article (PubMed ID: 4813575)
21. Immunocytochemically demonstrated expression of epithelial membrane antigen and carcinoembryonic antigen by exfoliated urinary cells in patients with bladder cancer.
Tanaka K; Takashi M; Miyake K; Koshikawa T
Urol Int; 1994; 52(3):140-4. PubMed ID: 8203052
[TBL] [Abstract][Full Text] [Related]
22. Determination of carcinoembryonic antigen in tissue, serum and urine in patients with transitional cell carcinoma of the urinary bladder.
Jakse G; Rauschmeier H; Rosmanith P; Hofstädter F
Urol Int; 1983; 38(3):121-5. PubMed ID: 6868210
[TBL] [Abstract][Full Text] [Related]
23. Urine cytology, tumour markers and bladder cancer.
Halachmi S; Linn JF; Amiel GE; Moskovitz B; Nativ O
Br J Urol; 1998 Nov; 82(5):647-54. PubMed ID: 9839578
[No Abstract] [Full Text] [Related]
24. ABO (H) blood group antigens and carcinoembryonic antigens as indicators of malignant potential in patients with transitional cell carcinoma of the bladder.
Nakatsu H; Kobayashi I; Onishi Y; Igawa M; Ito H; Tahara E; Nihira H
J Urol; 1984 Feb; 131(2):252-7. PubMed ID: 6366250
[TBL] [Abstract][Full Text] [Related]
25. Immunologic reduction of bladder cancer recurrence rate.
Olsson CA; Chute R; Rao CN
J Urol; 1974 Feb; 111(2):173-6. PubMed ID: 4810758
[No Abstract] [Full Text] [Related]
26. [Blood and urinary values of CEA and CA 19-9 in patients with bladder carcinoma].
Cicigoi A; Rocca Rossetti S; Piantino P; Cerchier A
Minerva Med; 1986 Nov; 77(42-43):1983-7. PubMed ID: 3464851
[TBL] [Abstract][Full Text] [Related]
27. Behavior of epithelial differentiation antigens (carcinoembryonic antigen, epithelial membrane antigen, keratin and cytokeratin) in transitional cell carcinomas of the bladder.
Sánchez-Fernández de Sevilla MC; Morell-Quadreny L; Gil-Salom M; Pérez-Bacete M; Fenollosa-Entrena B; Llombart-Bosch A
Urol Int; 1992; 48(1):14-9. PubMed ID: 1376008
[TBL] [Abstract][Full Text] [Related]
28. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
29. Isoantigens A, B and H in urinary bladder carcinomas following radiotherapy.
Alroy J; Teramura K; Miller AW; Pauli BU; Gottesman JE; Flanagan M; Davisohn I; Weinstein RS
Cancer; 1978 May; 41(5):1739-45. PubMed ID: 647623
[TBL] [Abstract][Full Text] [Related]
30. Expression of CD15 antigen in urinary bladder transitional cell carcinoma.
Parham DM; Morton K; Coghill G; Robertson AJ; Kerr MA
J Clin Pathol; 1990 Jul; 43(7):541-3. PubMed ID: 1974266
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical evaluation of nonspecific cross reactive antigen and carcinoembryonic antigen (CEA) in urinary bladder carcinoma.
Asamoto M; Fukushima S; Tatemoto Y; Yamada K; Yuba R; Mori M
Anticancer Res; 1989; 9(2):319-26. PubMed ID: 2751258
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
[TBL] [Abstract][Full Text] [Related]
33. Squamous and glandular differentiation in urothelial bladder carcinomas. Histopathology, histochemistry and immunohistochemical expression of carcinoembryonic antigen.
López-Beltrán A; Martín J; García J; Toro M
Histol Histopathol; 1988 Jan; 3(1):63-8. PubMed ID: 2980209
[TBL] [Abstract][Full Text] [Related]
34. Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder.
Sánchez-Carbayo M; Herrero E; Megias J; Mira A; Espasa A; Chinchilla V; Soria F
J Urol; 1999 Apr; 161(4):1110-5. PubMed ID: 10081849
[TBL] [Abstract][Full Text] [Related]
35. Preliminary studies of sera and urine from patients with bladder cancer.
Hollinshead AC
Natl Cancer Inst Monogr; 1978 Dec; (49):193-7. PubMed ID: 219366
[TBL] [Abstract][Full Text] [Related]
36. Immunological characterization of cell lines establishing from malignant and normal human urothelium.
Vilien M; Wolf H; Rasmussen F
Eur J Cancer (1965); 1981 Mar; 17(3):321-7. PubMed ID: 7262169
[No Abstract] [Full Text] [Related]
37. Association between HLA antigens and bladder tumors.
Tokuç R; Akdaş A; Ozerkan K; Remzi D
Eur Urol; 1987; 13(3):207-9. PubMed ID: 3497040
[TBL] [Abstract][Full Text] [Related]
38. [Immunologic indices of patients with transitional cell carcinoma of the urinary bladder].
Bkhatta AD; Makhlin NV
Urol Nefrol (Mosk); 1984; (2):67-70. PubMed ID: 6372193
[No Abstract] [Full Text] [Related]
39. [Relations of clinicopathological findings to expression of ABH blood group and Thomsen-Friedenrich antigens in initially superficial papillary transitional cell carcinomas of the bladder developing subsequent malignant progression].
Yamada T; Fukui I; Yokogawa M; Oshima H
Nihon Hinyokika Gakkai Zasshi; 1988 Jun; 79(6):1049-53. PubMed ID: 3184579
[No Abstract] [Full Text] [Related]
40. [Low-grade and low-stage transitional carcinoma of the bladder. Review].
Escudero Barrilero A; Gutiérrez Sanz Gadea C; Hernández Fernández C; Romero Maroto J; Tallada Buñuel M; Perales Cabanas L
Actas Urol Esp; 1985; 9(3):203-8. PubMed ID: 3898736
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
